Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Vincent Milano acquired 870 shares of BioCryst Pharmaceuticals common stock on May 31, 2024, in lieu of a portion of his quarterly board member retainer.

Summary

• On May 31, 2024, Vincent Milano, a director of BioCryst Pharmaceuticals, acquired 870 shares of common stock.
• The shares were issued in lieu of 50% of his quarterly cash Board Member retainer, amounting to $11,250.
• The price per share was $6.46.
• Following the transaction, Milano directly owns 67,867 shares of BioCryst Pharmaceuticals.
• The transaction was reported on June 3, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction where a director receives shares as part of their compensation. It doesn't indicate any significant positive or negative outlook.

Positives

• The director's decision to take shares in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Directors often receive equity as part of their compensation, aligning their interests with those of shareholders. This is a common practice in the pharmaceutical industry.

Related Party Transactions

• The transaction involves a director receiving shares in lieu of cash compensation, which is a related party transaction.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a routine part of director compensation.

Key Dates